La cadena de opciones muestra datos clave de las opciones de acciones de Pasithea Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Pasithea Therapeutics..

Pasithea Therapeutics (NASDAQ:KTTA) Bolsa, Cadena de Opciones

Pasithea Therapeutics

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics Corp

News

ONCT

Oncternal Therapeutics Announced Workforce Reduction Effective December 2, 2024; Four Employees Will Remain In A Part-time Capacity In Connection With Exploration Of Strategic Alternatives; Expects $2.4M In Charges From Workforce Reduction

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) with a Buy and maintains $15 price target.

Price Target

Analyst Ratings

RVPH

D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $15 Price Target

Trading Ideas

Third Point 13F Shows Increased Stake In Intercontinental Exchange By 109% From 1,000,000 To 2,085,000 Shares; Live Nation Entertainment By 71% From 1,365,000 To 2,340,000 Shares; CRH By 215% From 650,000 To 2,050,000 Shares; Telephone & Data Systems By 27% From 2,266,060 To 2,875,000 Shares

Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.87) by 3.45 percent.

Earnings

Earnings Beats

Kodiak Sciences Q3 2024 GAAP EPS $(0.84) Beats $(0.87) Estimate

Offerings

Associated Banc-Corp Announces Proposed Common Stock Offering Of 11.5M Shares

ANSS

FERG

FLUT

LPLA

TSLA

Third Point 13F Shows Added Stake In Brookfield Corp With 4,725,000 Shares; Ferguson Enterprises With 965,000 Shares; Flutter Entertainment With 510,000 Shares; LPL Financial Holdings With 485,000 Shares; Carpenter Technology With 660,000 Shares; Tesla With 400,000 Shares; CVS Health Corp With 1,575,000 Shares; Ansys With 255,000 Shares; Hawaiian Electric Industries With 1,535,000 Shares; Clear Channel Outdoor Holdings With 850,000 Shares

ABVX

Abivax Q3 Total Principal Debt Outstanding €106.3M Down From €108.4M YoY

Events

ASTS

AST SpaceMobile Announced It Has Made Significant Strides Its Mission To Establish the First Space-Based Cellular Broadband Network

Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)&#8217;s chief financial officer and two other insiders have sold millions of dollars worth of shares following the election, <a href="https://www.benzinga.com/quote/DJT">according to SEC filings</a>. 
The Details: Trump Media's CFO and treasurer Phillip Juhan sold 320,000 shares on Friday, Nov. 8 at a price of $30.65 per share for a total of $9.8 million in stock, according to a Form 4 <a href="https://www.sec.gov/Archives/edgar/data/1849635/000147450624000239/xslF345X05/primary_doc.xml">filing.</a> On Monday, Juhan sold another 64,000 shares at $32.97 per share, or $2.11 million in stock, according to the same filing.
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a>
Juhan previously <a href="https://www.sec.gov/Archives/edgar/data/1849635/000114036124045278/ef20038154_424b3.htm">disclosed </a>a trading plan that revealed his intention to sell 400,000 Trump Media &amp; Technology shares by December 2025. Juhan still holds 265,798 shares of DJT, according to the filing, most of which are restricted stock units (RSUs) <a href="https://www.sec.gov/Archives/edgar/data/1849635/000147450624000234/xslF345X05/primary_doc.xml">awarded </a>to him on Nov. 5 that cannot be immediately sold.
One-quarter of Juhan's restricted stock units will become eligible for sale on Dec. 25, 2024, and the remaining shares will vest in quarterly installments through March 2027.
Scott Glabe, Trump Media's general counsel and secretary, on Friday sold 15,917 shares for $32.19 per share, or a total of $512,368, an SEC <a href="https://www.sec.gov/Archives/edgar/data/1849635/000147450624000240/xslF345X05/primary_doc.xml">filing </a>shows.&nbsp; Glabe still <a href="https://www.sec.gov/Archives/edgar/data/1849635/000147450624000236/xslF345X05/primary_doc.xml">holds</a> 336,576 restricted stock units in Trump Media which will vest according to the same schedule as Juhan's RSUs.
Eric Swider, director, sold 136,183 shares of DJT on Friday at $28.23 per share, or a total of $3.84 million in stock, according to his Form 4 <a href="https://www.sec.gov/Archives/edgar/data/1849635/000147450624000238/xslF345X05/primary_doc.xml">filing</a>. Swider disposed of all of his shares, but his company, Renatus Advisors, still owns 18,043 shares of Trump Media.
Benzinga reached out to Trump Media &amp; Technology Group for comment on the stock sales.
Donald Trump, the majority shareholder of Trump Media &amp; Technology, <a href="https://www.sec.gov/Archives/edgar/data/1849635/000147450624000146/xslF345X05/primary_doc.xml">holds</a> 114.75 million shares, representing about 60% of the company&#8217;s total shares. Trump <a href="https://www.benzinga.com/media/24/11/41853221/trump-says-he-wont-sell-trump-media-stock">denied rumors </a>of a potential share sale in a post on Truth Social last Thursday.&nbsp;
Trump said the rumors were &#8220;fake, untrue, and probably illegal,&#8221; likely spread by market manipulators or short sellers. He emphasized, &#8220;I have no intention of selling.&#8221;
DJT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Trump Media &amp; Technology shares were down 3.84% at $27.82 late in Thursday&#8217;s trading session.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Image: Shutterstock.

Social Media

Politics

Insider Trades

Movers

Trump Media Insiders Sell More Than $16 Million In DJT Stock

Precigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 12.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $953.00 thousand which missed the analyst consensus estimate of $1.25 million by 23.76 percent. This is a 30.89 percent decrease over sales of $1.38 million the same period last year.

Earnings Misses

PGEN

Precigen Q3 2024 GAAP EPS $(0.09) Misses $(0.08) Estimate, Sales $953.00K Miss $1.25M Estimate

Billionaire Elon Musk may have been one of the central figures in the 2024 presidential election and Republican voters now view him more favorably than a year ago after Donald Trump <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">won the election.</a>
What Happened: Musk endorsed Trump in the 2024 presidential election and<a href="https://www.benzinga.com/news/24/10/41353213/tesla-ceo-elon-musk-to-campaign-for-trump-in-pennsylvania-asks-attendees-to-support-free-speech-ther"> campaigned for the president-elect </a>in the key swing state of Pennsylvania.
Since helping Trump win the 2024 election, Musk has been <a href="https://www.benzinga.com/government/regulations/24/11/41931503/trump-forms-doge-with-elon-musk-and-vivek-ramaswamy-at-the-helm-will-it-impact-tesla-ceos-role-at-the-ev-giant-and-spacex">named to lead</a> the Department of Government Efficiency, or D.O.G.E for short, alongside Vivek Ramaswamy.
Musk will likely play a central role in the Trump administration going forward and it comes as Republicans have a more favorable opinion of the billionaire.
A Morning Consult <a href="https://pro.morningconsult.com/analysis/elon-musk-trump-administration-influence">poll </a>conducted on Nov. 6 and Nov. 7 after Trump won the election found that 72% of Republicans had a favorable view of Musk, up from 52% a year ago. The poll found that 17% of Republican had an unfavorable view of Musk. The remaining respondents said they had heard of Musk and had no opinion (10%) or had never heard of Musk (1%).
For comparison, here is how Musk's favorable and unfavorable ratings compare to other key Republican figures. The following are the percent of Republican voters who said they viewed each person favorable or unfavorable:
<ul>
<li>Donald Trump: 87% favorable, 11% unfavorable</li>
<li>Republicans in Congress: 83% favorable, 12% unfavorable</li>
<li>J.D. Vance: 74% favorable, 12% unfavorable</li>
<li>Mike Johnson: 39% favorable, 14% unfavorable</li>
<li>Mitch McConnell: 29% favorable, 37% unfavorable</li>
</ul>
The poll shows Musk's favorable rating ranking nearly the same as vice-president-elect Vance. Musk also is viewed more favorable by Republicans than that of Speaker of the House Johnson and current Senate Minority Leader McConnell.
Musk does have the second worst unfavorable rating at 17%, ranking only ahead of McConnell, who has often clashed with Trump and members of his own party.
The poll also found that 53% of Republicans said Musk should play "a major role" in the Trump administration moving forward. This ranked ahead of Robert F. Kennedy Jr., who saw 49% of Republican voters say he should play a major role moving forward.
You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/24/11/41856335/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-42">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: Musk is viewed much more favorably by Republican voters than Democrats and Independent voters according to the latest poll.
The poll found that Democratic voters view Musk more unfavorable (71%) than favorable (17%). This is a big change from a year ago when Musk had a favorable rating of 32% and unfavorable rating of 46% from Democratic voters.
Independent voters are also more likely to have an unfavorable view of Musk (48%) than a favorable one (36%). This is a change from a year ago when 40% had unfavorable views of Musk and 34% viewed him favorable.
Overall, Musk had a favorable rating of 42% and unfavorable rating of 45% across all voters, compared to 40% favorable and 36% unfavorable a year ago.
Morning Consult has conducted the poll asking for views on Musk four times based on the latest poll, with results coming for April 2022, June 2022, November 2023 and November 2024.
Musk had his highest overall favorable rating of 45% from all voters back in April 2022.
While Musk's favorable rating is up to 72% and his unfavorable rating was down compared to a year ago amongst Republican voters, Musk had a lower unfavorable rating from Republican voters of 13% back in April 2022.
One of the key questions moving forward is if Musk's support of Trump, who has been a vocal critic of electric vehicles will hurt Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
Based on the surging price of Tesla stock since the 2024 election, Tesla investors see a Trump win as a positive with shares up 14.8% on the day after the election. Tesla stock is up 24.6% since the closing price on Election Day.
Trump's win could see the end of federal credits for electric vehicles, which could be negative for the sector. Tesla may not lose as much as the company is profitable and has large scale compared to electric vehicle competitors.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/11/41887136/snl-parodies-elon-musk-and-donald-trump-after-2024-election-billionaire-says-show-is-out-of-touch-with-reality">SNL Parodies Elon Musk And Donald Trump After 2024 Election: Billionaire Says Show Is &#8216;Out Of Touch With Reality&#8217;</a></li>
</ul>
Image: Shutterstock

Elon Musk's Favorability With GOP Voters Nearly As High As J.D. Vance: How Views Of Billionaire Changed Among Political Parties

Chardan Capital analyst Keay Nakae downgrades Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) from Buy to Neutral.

Downgrades

ALUR

Chardan Capital Downgrades Allurion Technologies to Neutral

Bakkt Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(1.35) by 66.67 percent. The company reported quarterly sales of $328.400 million which beat the analyst consensus estimate of $16.400 million by 1.90K percent. This is a 60.35 percent increase over sales of $204.800 million the same period last year.

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Bakkt Hldgs Q3 2024 GAAP EPS $(0.45) Beats $(1.35) Estimate, Sales $328.400M Beat $16.400M Estimate

Financing

XCUR

Exicure Enters Into Purchase Agreements For $1.3M And $8.7M Equity Financing

Siyata Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(1.67) by 76.05 percent. The company reported quarterly sales of $5.863 million which missed the analyst consensus estimate of $6.000 million by 2.28 percent. This is a 218.30 percent increase over sales of $1.842 million the same period last year.

SYTA

Siyata Mobile Q3 2024 GAAP EPS $(0.40) Beats $(1.67) Estimate, Sales $5.863M Miss $6.000M Estimate

Exicure Q3 EPS $(0.57) Up From $(3.04) YoY

WIIM

ADGM

Adiago Medical Holdings shares are trading after the company reported better-than-expected Q3 financial results.

Contracts

AXON

Axon Wins Federal Government Contract To Supply Royal Canadian Mounted Police With Body-Worn Cameras; Terms Not Disclosed

Outlook
Post management expects Adjusted EBITDA for fiscal year 2025 to be between $1,410-$1,460 million. Post management expects fiscal year 2025 capital expenditures to range between $380-$420 million, which includes Post Consumer Brands investment in network optimization and pet food safety and capacity, for aggregate expenditures of $90-$100 million. This also includes Foodservice investment in the completion of the Norwalk, Iowa precooked egg facility expansion and continued cage-free egg facility expansion, for aggregate expenditures of $80-$90 million.
Post provides Adjusted EBITDA guidance only on a non-GAAP basis and does not provide a reconciliation of its forward-looking Adjusted EBITDA non-GAAP guidance measure to the most directly comparable GAAP measure due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for income/expense on swaps, net, gain/loss on extinguishment of debt, net, integration and transaction costs, mark-to-market adjustments on commodity and foreign exchange hedges, mark-to-market adjustments and impairments on equity securities and investments, equity method investment adjustment and other charges reflected in Post's reconciliations of historical numbers, the amounts of which, based on historical experience, could be significant. For additional information regarding Post's non-GAAP measures, see the related explanations presented under "Use of Non-GAAP Measures."

Guidance

POST

Post Management Expects Adjusted EBITDA For FY25 To Be Between $1.410B-$1.460B; Capital Expenditures To Range Between $380M-$420M

BRLS

Borealis Foods Q3 EPS $(0.23) Up From $(0.61) YoY, Net Revenue $7.69M Down From $7.72M YoY

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ReShape Lifesciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>) stock is rising higher on Wednesday following approval from the Food and Drug Administration (FDA) for <a href="https://finance.yahoo.com/news/reshape-lifesciences-receives-fda-pma-210500500.html">a PMA supplement</a>.



That a PMA supplement applies to the company&rsquo;s Lap-Band 2.0 FLEX. This is the company&rsquo;s minimally invasive, long-term treatment of obesity.



Paul Hickey, president and CEO of ReShape Lifesciences, explains the differences the come with its updated Lap-Band 2.0 FLEX product.




&ldquo;Compared to our current Lap-Band, the Lap-Band&reg; 2.0 has a new feature called FLEX Technology, which acts as a relief valve, allowing larger pieces of food to more easily pass through the narrowed passage (or stoma), created by the band. Specifically, the band momentarily relaxes before returning to its resting diameter, therefore, minimizing discomfort caused by passage of large food pieces through the stoma.&rdquo;




<h2>What This Means for RSLS Stock</h2>



Improvement of its weight loss product is a positive for ReShape Lifesciences. The FDA approval also allows puts it closer to market, which could mean more revenue for the company.



With this news comes heavy trading of RSLS stock. As of this writing, around 50 million shares have changed hands. That&rsquo;s a massive leap in trading volume compared to the company&rsquo;s daily average of about 4 million shares.



RSLS stock is up 67.7% as of Wednesday morning.



There&rsquo;s more stock market news worth reading about below!



We have all of the hottest stock market news traders need to know about on Wednesday! Among that is what&rsquo;s happening with shares of Pasithea Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>), Loop Media&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>)&nbsp;and Innovative International&nbsp;Acquisition&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ioac-stock-quote/">IOAC</a>) stock. You can find out more on these matters down below!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/">Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-loop-media-lptv-stock-down-16-today/">Why Is Loop Media (LPTV) Stock Down 16% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-innovative-international-ioac-stock-up-31-today/">Why Is Innovative International (IOAC) Stock Up 31% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;<a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;&nbsp;<a href="http://investorplace.com/" target="_blank">InvestorPlace.com</a>&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.&nbsp;



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/why-is-reshape-lifesciences-rsls-stock-up-68-today/">Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Palantir Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/pltr-stock-quote/">PLTR</a>) stock is in the news Wednesday after the big data company <a href="https://finance.yahoo.com/news/palantir-renews-digital-transformation-partnership-115900977.html">renewed a contract</a> with UniCredit.



According to a press release from Palantir, UniCredit has renewed its partnership with the company for another five years. That will see it make use of the Palantir Foundry operating system to enhance its digital transformation.



Investors will note that Palantir and UniCredit first started working together in 2018. Over those five years, UniCredit saw significant benefits from the Palantir Foundry operating system. That even resulted in it expanding the use of the technology to all CE&amp;EE UniCredit Legal Entities.



Josh Harris, a Palantir executive, said the following about this partnership.




&ldquo;Palantir has long been a proud partner to some of the world&rsquo;s top financial institutions. We&rsquo;re honored that UniCredit has placed its confidence in Palantir once again and look forward to furthering the bank&rsquo;s digital transformation.&rdquo;




<h2>PLTR Stock Movement on Wednesday</h2>



With this recent news comes some 7 million shares of PLTR stock changing hands. That&rsquo;s still a ways off from its daily average trading volume of about 61 million shares. The stock is also down 1.3% as of Wednesday morning despite the renewed contract. However, PLTR is up 170.4% year-to-date.



Investors looking for more of the latest stock market news will want to keep reading!



We have all of the hottest stock market news worth checking out on Wednesday! A few examples of that include what&rsquo;s happening with ReShape Lifesciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>), Pasithea Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) and Loop Media&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>) stock. You can find more on these matters below!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/12/why-is-reshape-lifesciences-rsls-stock-up-68-today/">Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/">Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-loop-media-lptv-stock-down-16-today/">Why Is Loop Media (LPTV) Stock Down 16% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/pltr-stock-palantir-renews-unicredit-partnership/">PLTR Stock: Palantir Renews UniCredit Partnership</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PLTR Stock: Palantir Renews UniCredit Partnership

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Roblox (NYSE:<a href="https://investorplace.com/stock-quotes/rblx-stock-quote/">RBLX</a>) stock is on the move Wednesday as investors react to new coverage of the video game company&rsquo;s shares from Wells Fargo.



Wells Fargo analysts <a href="https://www.investing.com/news/stock-market-news/roblox-ads-to-become-significant-earnings-stream-over-time--wells-fargo-432SI-3255780">initiated coverage of RBLX stock</a> with an &ldquo;overweight&rdquo; rating. To put that in perspective, the analysts&rsquo; consensus rating for RBLX shares is moderate buy based on 22 opinions.



In addition to that, the company started its coverage of RBLX stock with a price target of $49 per share. That represents a potential upside of 16.6%. It&rsquo;s also bullish next to the analysts&rsquo; consensus price prediction of <a href="https://www.marketbeat.com/stocks/NYSE/RBLX/price-target/">$41.62 per share</a>.



<h2>Why the Bull Rating for RBLX Stock?</h2>



Here&rsquo;s what the Wells Fargo analysts had to say about Roblox in a note to clients obtained by Investing.com.




&ldquo;Similar to other audience platforms, we expect ads to become a significant earnings stream over time for Roblox, supported by strong user engagement. See meaningful upside to consensus bookings and EBITDA as we believe the ads opportunity is underappreciated by the Street, which has yet to properly capture future ad bookings into forecasts.&rdquo;




RBLX stock is up 2.5% as of Wednesday morning. This comes with more than 3.8 million shares traded. For the record, the company&rsquo;s daily average trading volume is still above that at 10.5 million shares.



Investors who want more of the latest stock market news are in luck!



We&rsquo;ve got all of the hottest stock market stories that traders need to know about on Wednesday! That includes everything going on with Palantir Technologies&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/pltr-stock-quote/">PLTR</a>) stock, ReShape Lifesciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>) stock and Pasithea Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) stock. You can find out more on these matters at the following links!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/12/pltr-stock-palantir-renews-unicredit-partnership/">PLTR Stock: Palantir Renews UniCredit Partnership</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-reshape-lifesciences-rsls-stock-up-68-today/">Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/">Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/rblx-stock-alert-wells-fargo-initiates-roblox-coverage-with-overweight-rating/">RBLX Stock Alert: Wells Fargo Initiates Roblox Coverage With &#8216;Overweight&#8217; Rating</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RBLX Stock Alert: Wells Fargo Initiates Roblox Coverage With 'Overweight' Rating

Pasithea conducts 1-for-20 reverse stock split, gets FDA okay for study

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares on the final day of trading this week!



Moving stocks today are public offerings, an earnings report and more.



Let&rsquo;s dive into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Aclarion (NASDAQ:<a href="https://investorplace.com/stock-quotes/acon-stock-quote/">ACON</a>) stock is rocketing more than 79% alongside heavy pre-market trading.</li>



<li>Himalaya Shipping (NYSE:<a href="https://investorplace.com/stock-quotes/hshp-stock-quote/">HSHP</a>) shares are soaring over 21% without any clear news this morning.</li>



<li>Ekso Bionics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ekso-stock-quote/">EKSO</a>) stock is surging more than 20% with strong early morning trading.</li>



<li>Panbela Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbla-stock-quote/">PBLA</a>) shares are gaining over 19% as it prepares for a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318006293&amp;type=PDF&amp;symbol=PBLA&amp;cdn=255e23064a07775ab2cefc841a6dd3b1&amp;companyName=Panbela+Therapeutics+Inc.&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2024-01-25">proposed public offering</a>.</li>



<li>Ucommune International (NASDAQ:<a href="https://investorplace.com/stock-quotes/uk-stock-quote/">UK</a>) stock is increasing more than 18% on Friday morning.</li>



<li>The Real Brokerage (NASDAQ:<a href="https://investorplace.com/stock-quotes/reax-stock-quote/">REAX</a>) shares are rising over 18% after <a href="https://www.nasdaq.com/press-release/the-real-brokerage-invites-you-to-join-us-at-the-microcap-conference-2024-01-25">announcing a presentation next week</a>.</li>



<li>BIT Mining Limited (NYSE:<a href="https://investorplace.com/stock-quotes/btcm-stock-quote/">BTCM</a>) stock is climbing more than 16% on Friday.</li>



<li>Lixiang Education (NASDAQ:<a href="https://investorplace.com/stock-quotes/lxeh-stock-quote/">LXEH</a>) shares are getting an over 15% boost after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318005286&amp;type=PDF&amp;symbol=LXEH&amp;cdn=6639882602bf7fce8ca884d95ec782b1&amp;companyName=Lixiang+Education+Holding+Co.+Ltd.&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-01-25">regaining Nasdaq compliance</a>.</li>



<li>Porch Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/prch-stock-quote/">PRCH</a>) stock is jumping more than 14% <a href="https://www.nasdaq.com/press-release/porch-group-receives-%2425m-with-signing-of-strategic-agreement-with-aon-2024-01-25">alongside a strategic agreement</a>.</li>



<li>Pasithea Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) shares are up over 14% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Aptose Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/apto-stock-quote/">APTO</a>) stock is plummeting more than 26% as <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318008758&amp;type=PDF&amp;symbol=APTO&amp;cdn=12b3da5a3896f2a507db32324ce6eb5a&amp;companyName=Aptose+Biosciences+Inc.&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-01-25">a public offering goes into effect</a>.</li>



<li>SU Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUGP#NASDAQ">SUGP</a>) shares are diving over 21% following its recent <a href="https://www.nasdaq.com/press-release/su-group-holdings-limited-announces-pricing-of-initial-public-offering-2024-01-23">initial public offering (IPO)</a>.</li>



<li>Eve&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/evex-stock-quote/">EVEX</a>) stock is tumbling more than 19% despite a lack of news.</li>



<li>Paramount Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/para-stock-quote/">PARA</a>) shares are retreating over 18% after <a href="https://investorplace.com/2024/01/para-stock-alert-is-david-ellison-about-to-take-paramount-global-private/">rising yesterday on acquisition reports</a>.</li>



<li>LAVA Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/lvtx-stock-quote/">LVTX</a>) stock is taking a more than 12% beating <a href="https://www.marketwatch.com/story/lava-therapeutics-shares-rise-as-drug-set-for-test-with-merck-s-keytruda-c936d7cd">after rallying yesterday</a>.</li>



<li>Nxu (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxu-stock-quote/">NXU</a>) shares are dropping over 12% after <a href="https://www.nasdaq.com/press-release/nxu-submits-for-nevi-grant-funding-to-enhance-its-major-highway-electrification-goals">seeking new grant funding</a>.</li>



<li>Sagimet Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgmt-stock-quote/">SGMT</a>) stock is decreasing more than 11% with <a href="https://finance.yahoo.com/news/sagimet-biosciences-announces-proposed-public-224500288.html">public offering plans</a>.</li>



<li>Integrated Media Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/imte-stock-quote/">IMTE</a>) shares are falling over 11% on Friday.</li>



<li>Intel (NASDAQ:<a href="https://investorplace.com/stock-quotes/intc-stock-quote/">INTC</a>) stock is sliding more than 10% with <a href="https://www.cnbc.com/2024/01/25/intel-intc-earnings-report-q4-2023.html">Q4 earnings results</a>.</li>



<li>Clearmind Medicine (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmnd-stock-quote/">CMND</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/01/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-jan-26th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pasithea Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) just reported results for the first quarter of 2024.<ul><li>Pasithea Therapeutics reported earnings per share of -$3.70.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ktta-stock-earnings-pasithea-therapeutics-for-q1-of-2024/">KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pasithea Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) just reported results for the fourth quarter of 2023.<ul><li>Pasithea Therapeutics reported earnings per share of -$4.10.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/ktta-stock-earnings-pasithea-therapeutics-for-q4-of-2023/">KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pasithea Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) just reported results for the second quarter of 2024.<ul><li>Pasithea Therapeutics reported earnings per share of -$3.71.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ktta-stock-earnings-pasithea-therapeutics-for-q2-of-2024/">KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q2 2024

Pasithea Therapeutics drops 19% on $5M private placement

Pasithea Therapeutics files to sell 3.74M shares of common stock for holders

ACON

APTO

BTCM

CMND

EKSO

EVEX

HSHP

IMTE

INTC

IOAC

KTTA

KTTAW

LPTV

LVTX

LXEH

PARA

PBLA

PLTR

PRCH

RBLX

REAX

RSLS

SGMT

SUGP

Press Releases

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Health Care

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

General

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Technical Explosions: DUO, KTTA, TBIO, GOTU – Watch Peraso Inc. (NASDAQ: PRSO) Now Amid Breakout Momentum!

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Comments

Pasithea Therapeutics

Pasithea Therapeutics (KTTA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL